Skip to main content
. 2017 Feb 22;7:43023. doi: 10.1038/srep43023

Figure 4. ARCN1 is a potential target for cancer therapy.

Figure 4

(a) BJ-hTERT and HCT-116 were transfected with 5 nM individual siRNA (Qiagen) (Upper Panel). BJ-hTERT, MDA-MB-231, HCT-116, and PC3 cells were transfected with 2.5 nM of pooled siRNAs (GE Healthcare) (Lower Panel). Cell number, representation, and statistical tests were done as in Fig. 3. P-values are <0.0063 and All <0.0001 for Upper and Lower Panels respectively. All siRNA transfections performed in 4 replicates. (b) ARCN1 and COPZ1 expression were analyzed by WB in MDA-MB-231 and BJ-hTERT cells. Cells were transfected with control, ARCN1, or COPZ1 siRNAs (2.5 nM, GE Healthcare pooled siRNAs). Cells were lysed 72 hrs post-transfection followed by WB analysis of β-Actin, ARCN1, or COPZ1 proteins with corresponding antibodies. (c) BJ-hTERT and MDA-MB-231 cells were transfected with COPZ1, ARCN1, and control siRNA (as in (b)). Golgi and cell nuclei were visualized by IF with anti-GM130 and DAPI. Depletion of ARCN1 results in Golgi disruption (no distinct tubular structure) in both normal (BJ-hTERT) and cancer cells (MDA-MB-231), while depletion of COPZ1 by siRNA results in selective disruption of the Golgi in cancer cells without affecting the Golgi in normal cells. (d) Association of ARCN1 expression with survival of gastric, breast, and ovarian cancer patients. Kaplan–Meier analysis performed as described in Fig. 3.